Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review

Rambam Maimonides Medical Journal 2026 Open access

Read full text
Authors: Randy Adiwinata, Caroline Tanadi, Fegita Beatrix Pajala, Kevin Tandarto, Maureen Miracle Stella, Jeffry Beta Tenggara, Ralph Girson Gunarsa, Paulus Simadibrata, Lianda Siregar, Saut Nababan, Budiman Sulaiman, Irsan Hasan
+2 more Cosmas Lesmana, Aru Wisaksono Sudoyo
DOI: 10.5041/rmmj.10571
Cited by: 0
References: 121

Abstract

Immunotherapy using immune checkpoint inhibitor (ICI) has been increasingly used in the oncology treatment field. Although ICIs could help suppress cancer and improve survival rates, it could also lead to certain adverse events, including immune-mediated liver injury caused by ICIs (ILICI). The manifestation of ILICI ranged greatly from asymptomatic disease to liver failure and even death. In this review article, we will discuss the pathogenesis, manifestation, and clinical approach of ILICI.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Drug-Induced Hepatotoxicity and Protection Hepatocellular Carcinoma Treatment and Prognosis

Publication details

Journal / source
Rambam Maimonides Medical Journal
Volume
17
Issue
1
Pages
e0005–e0005
Publication date
28 January 2026
Language
EN